MET and neoplasm: Moreover, Src frequently interacts with multiple growth factor receptors, such as EGFR, HER2/ErbB2, PDGFR, IGF-1R, and c-Met/HGFR, further enhancing downstream signalling and transcriptional activity that drive tumour growth and disease progression.